ICCC FY 2022 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M-3.5% YoY

Gross Profit

$8M41.2% margin

Operating Income

-$2M-12.4% margin

Net Income

-$2M-13.4% margin

EPS (Diluted)

$-0.32

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$6M

Stock-Based Comp.

$266,244

Balance Sheet

Total Assets

$45M

Total Liabilities

$14M

Stockholders' Equity

$30M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$19M	-3.5%
Gross Profit	$8M	$9M	-11.6%
Operating Income	-$2M	$257,385	-993.2%
Net Income	-$2M	-$78,292	-3085.5%